We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

End-stage Renal Disease (ESRD) Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03787368
Recruitment Status : Completed
First Posted : December 26, 2018
Last Update Posted : March 16, 2022
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.

Condition or disease Intervention/treatment Phase
Renal Dialysis Drug: BAY1213790 Drug: 0.9% sodium chloride solution Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Patients, investigators, and all other site staff will remain blinded for the administered BAY1213790 or placebo, with the exception of the unblinded pharmacist or specifically dedicated site personnel.The sponsor will be not be blinded. Bioanalysis of plasma concentrations and PD parameters, as well as the evaluation of results will be performed in a non-blinded fashion.
Primary Purpose: Treatment
Official Title: An Observer-blind, Multi-center, Placebo-controlled, Parallel Group Study to Assess the Safety and Tolerability and to Characterize the Pharmacokinetics and the Pharmacodynamics of Different Doses of BAY1213790 in Patients With End-stage Renal Disease Undergoing Hemodialysis
Actual Study Start Date : January 31, 2019
Actual Primary Completion Date : September 15, 2021
Actual Study Completion Date : September 15, 2021

Arm Intervention/treatment
Experimental: Dose 1 of BAY1213790
Single intravenous infusion BAY1213790 (Dose 1)
Drug: BAY1213790
Single intravenous infusion of BAY1213790 (Two different doses)

Experimental: Dose 2 of BAY1213790
Single intravenous infusion BAY1213790 (Dose 2)
Drug: BAY1213790
Single intravenous infusion of BAY1213790 (Two different doses)

Placebo Comparator: Placebo
Single intravenous infusion placebo
Drug: 0.9% sodium chloride solution
Single intravenous infusion of Placebo (0.9% sodium chloride solution)

Primary Outcome Measures :
  1. Number of major and CRNM bleeding events [ Time Frame: Approx. 4 weeks (Before study drug or placebo administration) ]
    CRNM bleeding: Clinically Relevant Non-Major bleeding

  2. Number of major and CRNM bleeding events [ Time Frame: Approx. 4 weeks (After study drug or placebo administration) ]

Secondary Outcome Measures :
  1. AUC (AUC(0-tlast) will be used as main parameter if mean AUC(tlast-∞) >20% of AUC) [ Time Frame: Approx. 5 months (Pre-dose to follow up) ]
    AUC: Area under the concentration vs. time curve from zero to infinity after single (first) dose

  2. aPTT will be measured via the kaolin-trigger method (clotting assay) [ Time Frame: Approx. 6 months (Before study drug or placebo administration to follow up) ]
    aPTT: activated Partial Thromboplastin Time

  3. Factor XI activity will be assessed with an aPTT-based coagulation test using FXI [ Time Frame: Approx. 6 months (Before study drug or placebo administration to follow up) ]
    FXI: Factor XI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Male and female patients between 18 and 80 years of age.
  • ESRD on hemodialysis (including hemodiafiltration) for at least 3 months
  • Life expectancy of > 6 months
  • Women of non-childbearing potential

Exclusion Criteria:

  • High risk for clinically significant bleeding
  • Acute renal failure
  • Planned major surgery in the next 7 months from randomization
  • Concomitant use of oral anticoagulant therapy or antiplatelet therapy
  • Documented thrombotic event in the past 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787368

Layout table for location information
United States, California
California Institute of Renal Research - Chula Vista
Chula Vista, California, United States, 91910
United States, Florida
Nova Clinical Research, LLC
Bradenton, Florida, United States, 34209
United States, Illinois
Research by Design, LLC
Chicago, Illinois, United States, 60643
United States, Massachusetts
Renal and Transplant Associates of New England, PC
Springfield, Massachusetts, United States, 01107
CHU de Charleroi Hôpital civil
Lodelinsart, Hainaut, Belgium, 6042
UZ Brussel
Bruxelles - Brussel, Belgium, 1090
UZ Leuven Gasthuisberg
Leuven, Belgium, 3000
CHLO - Hospital Santa Cruz
Carnaxide, Lisboa, Portugal, 2795-53
Pluribus Dialise - Cascais (DaVita)
Cascais, Lisboa, Portugal, 2750-663
CHMT - Hospital Rainha Santa Isabel
Torres Novas, Santarém, Portugal, 2350-754
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain, 15706
Ciutat Sanitària i Universitària de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Reina Sofía
Córdoba, Spain, 14004
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Hospital Universitario Dr. Peset
Valencia, Spain, 46017
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03787368    
Other Study ID Numbers: 20046
2018-003109-24 ( EudraCT Number )
First Posted: December 26, 2018    Key Record Dates
Last Update Posted: March 16, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
End-stage renal disease patients undergoing hemodialysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency